Evidence map›Paper›PMID 39180477›Full record

Trial reportJournal of the National Cancer Institute2024

Inflammation, physical activity, and disease-free survival in stage III colon cancer: Cancer and Leukemia Group B-Southwest Oncology Group 80702 (Alliance).

Justin C Brown, Chao Ma, Qian Shi, Felix Couture, Philip Kuebler, Pankaj Kumar, Benjamin Tan, Smitha Krishnamurthi, Victor Chang, Richard M Goldberg and 3 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the National Cancer Institute, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Justin C BrownPennington Biomedical Research Center, Baton Rouge, LA, USA.ORCID 0000-0001-7540-4913
Chao MaDana-Farber Cancer Institute, Boston, MA, USA.
Qian ShiAlliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN, USA.ORCID 0000-0002-4640-8832
Felix CoutureHôtel-Dieu de Québec, Québec, Canada.
Philip KueblerColumbus National Cancer Institute Community Oncology Research Program, Columbus, OH, USA.
Pankaj KumarHeartland Cancer Research NCI Community Oncology Research Program, Illinois CancerCare PC, Peoria, IL, USA.
Benjamin TanSiteman Cancer Center, Washington University School of Medicine, Saint Louis, MO, USA.
Smitha KrishnamurthiCleveland Clinic, Cleveland, OH, USA.
Victor ChangVeterans Administration New Jersey Health Care System, East Orange, NJ, USA.ORCID 0000-0003-3640-7235
Richard M GoldbergWest Virginia University Cancer Institute, Morgantown, WV, USA.
Eileen M O'ReillyMemorial Sloan Kettering Cancer Center, Weill Cornell Medical Center, New York, NY, USA.
Anthony F ShieldsKarmanos Cancer Institute, Wayne State University, MI, USA.ORCID 0000-0002-9122-1014
Jeffrey A MeyerhardtDana-Farber Cancer Institute, Boston, MA, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI FRANCESCA M GANY · 1985 to 2026
$347.4M
NRG Oncology Network Group Operations Center - GY9 BIQSFP Reports/BudgetsU10CA180868 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI NORMAN WOLMARK · 2014 to 2026
$206.8M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Project-006U10CA180820 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer · 2014 to 2026
$167.6M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · 2014 to 2026
$152.1M
NRG Oncology NCORP Research Base-BIQSFPUG1CA189867 · NCI · NRG ONCOLOGY FOUNDATION, INC. · PI Deborah Watkins Bruner, Lisa A. Kachnic · 2014 to 2026
$140.5M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
Heartland Cancer Research NCORPUG1CA189830 · NCI · DECATUR MEMORIAL HOSPITAL · PI Bryan Faller · 2014 to 2026
$40.9M
NCIC Clinical Trials Group - Canadian Collaborating Clinical Trials NetworkU10CA180863 · NCI · QUEEN'S UNIVERSITY AT KINGSTON · PI Janet Ellen Dancey · 2014 to 2026
$40.4M
WASHINGTON UNIVERSITY / SITEMAN CANCER CENTER LEAD ACADEMIC SITEUG1CA233339 · NCI · WASHINGTON UNIVERSITY · PI NANCY L BARTLETT, Clifford Grant Robinson · 2019 to 2026
$11.3M
Case Comprehensive Cancer Center NCTN Lead Academic Participating SiteUG1CA233234 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI Aaron Thomas Gerds, Daniel Eidelberg Spratt · 2019 to 2026
$11.1M
Network Lead Academic Participating Site: Memorial Sloan Kettering Cancer CenterUG1CA233290 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CAROL AGHAJANIAN, Darren Feldman · 2019 to 2026
$10.2M
Alliance for Clinical Trials in Oncology UG1CA233180American Institute for Cancer ResearchAnonymous Family Fund for Innovations in Colorectal CancerAstra ZenecaAstraZenecaCanadian Cancer Trials Group U10CA180820Cancer Research UKCelgene-Bristol Myers Squibb and RocheColumbus National Community Oncology Research ProgramDouglas Gray Woodruff ChairECOG-ACRIN Cancer Research Group U10CA180868GenentechGeorge Stone Family FoundationNational Institutes of CancerNCI NIH HHS OT2 CA278684NCI NIH HHS P30 CA008748NCI NIH HHS R00 CA218603NCI NIH HHS R01 CA270274NCI NIH HHS U01 CA271279NCI NIH HHS U10 CA180820NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180863NCI NIH HHS U10 CA180868NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA189830NCI NIH HHS UG1 CA189867NCI NIH HHS UG1 CA189954NCI NIH HHS UG1 CA233163NCI NIH HHS UG1 CA233180NCI NIH HHS UG1 CA233234NCI NIH HHS UG1 CA233290NCI NIH HHS UG1 CA233339NIH HHSNIH HHS U10CA180821NRG Oncology U10CA180888SWOG Cancer Research Group R00CA218603
6 · The paper itself

Abstract

backgroundInflammation and insufficient physical inactivity contribute to individual-level risk of disease recurrence and death in stage III colon cancer. The extent to which increased inflammatory risk can be offset by sufficient physical activity remains unknown.

methodsThis cohort study was nested within the Cancer and Leukemia Group B (now part of the Alliance for Clinical Trials in Oncology) and Southwest Oncology Group randomized trial. Inflammatory burden was quantified by high-sensitivity C-reactive protein, interleukin-6, and soluble tumor necrosis factor-α receptor 2 after recovery from tumor resection. Physical activity was measured during and after postoperative chemotherapy. The primary endpoint was disease-free survival.

resultsThe 3-year disease-free survival rate was 88.4% among patients with low inflammation and sufficient physical activity (referent group for all comparisons), 84.9% with low inflammation and insufficient physical activity (absolute risk difference = -3.5 percentage points, 95% confidence interval [CI] = -11.3 to 4.3; P = .38), 78.0% with intermediate inflammation and insufficient physical activity (absolute risk difference = -10.4 percentage points, 95% CI = -17.4 to -3.3; P = .007), and 79.7% with high inflammation and insufficient physical activity (absolute risk difference = -8.7 percentage points, 95% CI = -15.7 to -1.6; P = .022). In contrast, the 3-year disease-free survival rate was 87.3% among patients with intermediate inflammation and sufficient physical activity (absolute risk difference = -1.1 percentage points, 95% CI = -7.5 to 5.3; P = .74) and 84.4% with high inflammation and sufficient physical activity (absolute risk difference = -4.0 percentage points, 95% CI = -12.3 to 4.3; P = .34).

conclusionIn this observational study of stage III colon cancer patients, physical activity was associated with improved disease-free survival despite high inflammation. Patients with intermediate or high inflammation who were physically active had disease-free survival rates that were not statistically significantly different from those with low inflammation.

Indexed as

Colonic NeoplasmsExerciseInflammationNeoplasm StagingAgedCohort StudiesC-Reactive ProteinDisease-Free SurvivalFemaleHumansInterleukin-6MaleMiddle AgedNeoplasm Recurrence, LocalC-Reactive ProteinInterleukin-6

Identifiers

PMID39180477
PMCPMC11630502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.